Lymphoma: turning biology into cures
Lymphoma: turning biology into cures
Diffuse large B-cell lymphoma (DLBCL) is the commonest aggressive non-Hodgkin lymphoma with approximately 5,000 cases annually in the UK. The R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) regimen has become the international standard of care with cure rates of around 75% and despite extensive studies aimed at improving the outcomes, R-CHOP has not been superseded. Those patients that do not respond to R-CHOP have a poor outlook. DLBCL is a disease with marked molecular heterogeneity; advances in gene expression profiling and mutational analysis can be used to increase our understanding of the disease and identify new therapeutic targets. Precision medicine using new agents, including small molecule inhibitors, is now being investigated for DLBCL. Progress in this disease is likely to come by targeting heterogeneous subtypes through novel combinations. Where R-CHOP fails, we hope that these new approaches can succeed by providing personalised medicine using precision diagnostics to guide new treatment paradigms.
125-129
Cummin, Thomas
fcce88a2-7ed7-4bde-a5f5-3f3c834382a4
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
December 2016
Cummin, Thomas
fcce88a2-7ed7-4bde-a5f5-3f3c834382a4
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the commonest aggressive non-Hodgkin lymphoma with approximately 5,000 cases annually in the UK. The R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) regimen has become the international standard of care with cure rates of around 75% and despite extensive studies aimed at improving the outcomes, R-CHOP has not been superseded. Those patients that do not respond to R-CHOP have a poor outlook. DLBCL is a disease with marked molecular heterogeneity; advances in gene expression profiling and mutational analysis can be used to increase our understanding of the disease and identify new therapeutic targets. Precision medicine using new agents, including small molecule inhibitors, is now being investigated for DLBCL. Progress in this disease is likely to come by targeting heterogeneous subtypes through novel combinations. Where R-CHOP fails, we hope that these new approaches can succeed by providing personalised medicine using precision diagnostics to guide new treatment paradigms.
Text
TEC Turning Lymphoma. turning biology into cures
- Version of Record
More information
Accepted/In Press date: 4 December 2016
e-pub ahead of print date: 12 December 2016
Published date: December 2016
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 407737
URI: http://eprints.soton.ac.uk/id/eprint/407737
PURE UUID: 8f78a5d4-52d8-4bd2-b892-3a835d49ed7f
Catalogue record
Date deposited: 25 Apr 2017 01:04
Last modified: 16 Mar 2024 02:59
Export record
Altmetrics
Contributors
Author:
Thomas Cummin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
